Anti-Factor X | Activity

General Information

Anti-Factor Xa

(Anti-Factor Xa) test is used For monitoring anticoagulant therapy

Considering the stability period of the sample, the collection of research material will be carried out only at the central branch (Tbilisi, Tsinandali 9) on Tuesdays until 12:00.

Coagulation factor X

The deficiency may be congenital or acquired.
Coagulation factor X is a vitamin K-dependent serine protease (a protein with enzymatic activity) that is synthesized in the liver. Its biological half-life is 24 to 48 hours. Factor X participates in both the intrinsic and extrinsic cascades of coagulation, where it acts as an enzyme (factor Xa) in the prothrombinase complex.

Congenital deficiency of factor X is rare. Acquired deficiency is usually associated with liver disease, warfarin therapy, vitamin K deficiency, systemic amyloidosis, and inhibitors. Factor X deficiency results in increased prothrombin time and activated partial thromboplastin time.

Anti-Factor XaActivity is determined by aPTT (activated partial thromboplastin time)-based clotting time assay.

Referral norms:

Adults: 70-150%
Newborns with normal development time and also premature babies may have a decrease in the concentration of coagulation factor X levels (> or =15-20%)

Interpretation

A decrease in the activity of coagulation factor X characterizes such pathologies as:
• Amyloidosis – a rare condition when pathological protein-amyloid accumulates in the cells of organs and causes damage to the function and structure of the organ.
• Congenital deficiency of factor 10 as a result of F10-gene mutation
• Disseminated intravascular coagulation syndrome – a condition when the entire blood mass clots and blocks the lumen of blood vessels. This disrupts the blood supply to the tissues.
• Decreased ability to absorb fat - because factor 10 is a protein related to vitamin K, and vitamin K is fat-soluble.
• Heparin therapy – for the treatment or prevention of increased blood clotting
• Liver diseases
• Vitamin K deficiency

An increase in the activity of coagulation factor 10 is observed during pregnancy, when taking oral contraceptives. Increasing its activity increases the risk of thrombosis.